Veliparib, paclitaxel en carboplatine bij de behandeling van patiënten met solide tumoren die uitgezaaid zijn of niet kunnen worden verwijderd door een operatie en lever- of nierdisfunctie
Een vroege fase 1-studie van ABT-888 in combinatie met carboplatine en paclitaxel bij patiënten met lever- of nierdisfunctie en solide tumoren
This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver or kidney dysfunction. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with paclitaxel and carboplatin may kill more tumor cells.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. To determine the pharmacokinetics and pharmacodynamics of ABT-888 (veliparib) in patients with varying degrees of renal or hepatic dysfunction.
II. To determine the maximum tolerated dose (MTD) of ABT-888 in combination with carboplatin and paclitaxel for patients with varying degrees of liver or kidney dysfunction.
III. To provide dosing recommendations for ABT-888 in combination with carboplatin and paclitaxel based on degree of hepatic and renal impairment.
SECONDARY OBJECTIVES:
I. To define the dose-limiting toxicity (DLT) and other toxicities associated with the use of this combination in patients with varying degrees of renal or hepatic dysfunction.
II. To evaluate the pharmacokinetic parameters of ABT-888, carboplatin, and paclitaxel when administered as a combination in patients with varying degrees of renal or hepatic dysfunction.
III. To evaluate the pharmacodynamic measurement of poly-ADP-ribosylated (PAR) and platinum adducts in tumor cells associated with the use of this combination in patients with varying degrees of renal or hepatic dysfunction.
OUTLINE: This is a dose-escalation study of veliparib.
Patients receive veliparib* orally (PO) twice daily (BID) on days 1-7 and paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30 minutes on day 3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
NOTE: * All patients receive a single dose of veliparib PO on day -6 before course 1 (except patients with very severe renal dysfunction who receive veliparib on day -5 or -6 to coincide with a dialysis day).
After completion of study treatment, patients are followed up for 4 weeks.
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
California
-
Duarte, California, Verenigde Staten, 91010
- City of Hope Comprehensive Cancer Center
-
Sacramento, California, Verenigde Staten, 95817
- University of California Davis Comprehensive Cancer Center
-
South Pasadena, California, Verenigde Staten, 91030
- City of Hope South Pasadena
-
-
Florida
-
Tampa, Florida, Verenigde Staten, 33612
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Emory University Hospital/Winship Cancer Institute
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Detroit, Michigan, Verenigde Staten, 48201
- Wayne State University/Karmanos Cancer Institute
-
-
New Jersey
-
New Brunswick, New Jersey, Verenigde Staten, 08903
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
New York, New York, Verenigde Staten, 10065
- Memorial Sloan Kettering Cancer Center
-
The Bronx, New York, Verenigde Staten, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Verenigde Staten, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
Ohio
-
Cleveland, Ohio, Verenigde Staten, 44106
- Case Western Reserve University
-
-
Pennsylvania
-
Hershey, Pennsylvania, Verenigde Staten, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15232
- UPMC Hillman Cancer Center
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- UT MD Anderson Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, Verenigde Staten, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Patients must have histologically confirmed malignancy that is radiologically evaluable and metastatic or unresectable, for which standard curative or palliative measures do not exist or are no longer effective, and for which there is expectation of response to the combination of carboplatin/paclitaxel (i.e., lung, ovarian, breast, melanoma, head and neck, endometrial, urothelial, testicular, esophageal, carcinoma of unknown primary); for indications not listed, eligibility based on disease must be verified by the principal investigator before they are considered
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Life expectancy of greater than 12 weeks
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- Hemoglobin >= 8.0 g/dL
- Patients with all degrees of renal dysfunction are allowed including patients on hemodialysis; patients with mild to severe hepatic dysfunction are allowed as defined below:
- Total bilirubin =< 5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 10 x ULN
- For patients with a recently placed biliary stent, patients should have consistent results within a hepatic group from two laboratory readings within 3 days apart, taken at least 10 days following biliary stent placement; for patients with a biliary stent placed over 2 months ago, no obstruction or blockage can have occurred within the last 2 months
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those whose adverse event due to agents administered more than 4 weeks earlier have not resolved or stabilized; patients who have been administered ABT-888 as part of a single or combination, phase 0 or I study, should not necessarily be excluded from participating in this study solely because of receiving prior ABT-888
- Patients may not be receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study
- Peripheral neuropathy of severity greater than grade 1
- Inability to take oral medications on a continuous basis
- Evidence of bleeding diathesis
- Patients with central nervous system (CNS) metastases must be stable after therapy for CNS metastases (such as surgery, radiotherapy or stereotactic radiosurgery) for at least 3 months and must be off steroid treatment prior to study enrollment
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888; these potential risks may also apply to other agents used in this study
- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV-positive patients without an acquired immune deficiency syndrome (AIDS)-defining diagnosis who are not receiving agents with the potential for pharmacokinetic (PK) interactions with ABT-888 may be eligible
- Patients with both hepatic and renal dysfunction will also be excluded
- Patients who received and progressed on the combination of carboplatin/paclitaxel will not be eligible
- Active seizure or history of seizure disorder
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Treatment (veliparib, paclitaxel, carboplatin)
Patients receive veliparib* PO BID on days 1-7 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 3. Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. NOTE: * All patients receive a single dose of veliparib PO on day -6 before course 1 (except patients with very severe renal dysfunction who receive veliparib on day -5 or -6 to coincide with a dialysis day). |
Given IV
Andere namen:
Given IV
Andere namen:
Correlative studies Given PO
Andere namen:
Correlative studies |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
MTD van veliparib in combinatie met carboplatine en paclitaxel, bepaald volgens de incidentie van DLT zoals ingedeeld volgens de National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) versie (v) 4.0
Tijdsspanne: 21 dagen
|
21 dagen
|
|
|
PK parameters of veliparib
Tijdsspanne: Day -6 and 3 of course 1 after veliparib dosing
|
Standard quantitative and graphical statistical summaries of the derived PK parameters (e.g. area under curve and clearance) will be produced for each organ function cohort. The effect of dysfunction on pharmacokinetics will be explored by comparing each pharmacokinetic parameter across all cohorts using one-way analysis (analysis of variance) or Kruskal-Wallis test. The level of each protein will be compared between responders and non-responders using the Wilcoxon signed rank test. |
Day -6 and 3 of course 1 after veliparib dosing
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidence of toxicities as assessed by NCI CTCAE v4.0
Tijdsspanne: Up to 4 weeks after completion of study treatment
|
The maximum grade of toxicity for each category of interest will be recorded for each patient and the summary results will be tabulated by category, grade and dose level. Severe and life-threatening toxicities and adverse event-related deaths (>= grade 3) will be described on a patient-by-patient basis and will include any relevant baseline data. |
Up to 4 weeks after completion of study treatment
|
|
Response rate as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Tijdsspanne: Up to 4 weeks after completion of study treatment
|
Responses will be tabulated by disease diagnosis and by dose level. 95% confidence limits will also be reported on the response rates. |
Up to 4 weeks after completion of study treatment
|
|
Incidence of stable disease as assessed by RECIST version 1.1
Tijdsspanne: Up to 4 weeks after completion of study treatment
|
Incidence of stable disease will be tabulated by disease diagnosis and by dose level. |
Up to 4 weeks after completion of study treatment
|
|
Time to progression
Tijdsspanne: Up to 4 weeks after completion of study treatment
|
Displayed for all patients and for patients who have responded; no formal statistical analysis is planned. |
Up to 4 weeks after completion of study treatment
|
Andere uitkomstmaten
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in PAR levels
Tijdsspanne: Baseline to up to 4 weeks
|
Descriptive statistics (mean, standard deviation, median, range) for measurements of PAR levels will provided with 95% confidence intervals (CIs). When sample size permits, a formal statistical test using the Wilcoxon signed rank test will be used to compare the post treatment PAR levels to the baseline levels. When feasible, the level will be compared between responders and non-responders using the Wilcoxon signed rank test. |
Baseline to up to 4 weeks
|
|
Change in gamma-H2AX levels
Tijdsspanne: Baseline to up to 4 weeks
|
Descriptive statistics (mean, standard deviation, median, range) for measurements of gamma-H2AX levels will provided with 95% CIs. When sample size permits, a formal statistical test using the Wilcoxon signed rank test will be used to compare the post treatment PAR levels to the baseline levels. When feasible, the level will be compared between responders and non-responders using the Wilcoxon signed rank test. |
Baseline to up to 4 weeks
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Hussein A Tawbi, University of Pittsburgh Cancer Institute (UPCI)
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Werkelijk)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Endocriene systeemziekten
- Pathologische processen
- Genitale neoplasmata, mannelijk
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Genitale ziekten, man
- Mannelijke urogenitale ziekten
- Nier Ziekten
- Urologische ziekten
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Ziekten van de luchtwegen
- Neoplasmata per histologisch type
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Baarmoeder Ziekten
- Genitale ziekten, vrouw
- Longziekten
- Endocriene klierneoplasmata
- Lever Ziekten
- Neoplasmata, glandulair en epitheel
- Neoplasmata van de luchtwegen
- Thoracale neoplasmata
- Neoplastische processen
- Slokdarmaandoeningen
- Ovariële ziekten
- Adnexale ziekten
- Genitale neoplasmata, vrouwelijk
- Gonadale aandoeningen
- Huidziektes
- Borst ziekten
- Carcinoom
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Baarmoeder Neoplasmata
- Neuro-endocriene tumoren
- Nevi en melanomen
- Huidneoplasmata
- Leverinsufficiëntie
- Testiculaire ziekten
- Pathologische aandoeningen, tekenen en symptomen
- Huid- en bindweefselaandoeningen
- Longneoplasmata
- Slokdarmneoplasmata
- Ovariumneoplasmata
- Borstneoplasmata
- Neoplasma metastase
- Hoofd- en nekneoplasmata
- Melanoma
- Endometriumneoplasmata
- Nierinsufficiëntie
- Carcinoom, overgangscel
- Leverfalen
- Neoplasmata, onbekend primair
- Testiculaire neoplasmata
- Organische chemicaliën
- Koolwaterstoffen
- Cycloparaffins
- Koolwaterstoffen, alicyclisch
- Koolwaterstoffen, cyclisch
- Terpenen
- Coördinatiecomplexen
- Taxoids
- Cyclodecanes
- Diterpenen
- Gezondheidszorg economie en organisaties
- Economie
- Carboplatine
- Paclitaxel
- veliparib
- Belastingen
Andere studie-ID-nummers
Andere studie-ID-nummers
- NCI-2011-02500
- U01CA070095 (Subsidie/contract van de Amerikaanse NIH)
- UM1CA186691 (Subsidie/contract van de Amerikaanse NIH)
- UM1CA186716 (Subsidie/contract van de Amerikaanse NIH)
- U01CA099168 (Subsidie/contract van de Amerikaanse NIH)
- U01CA062502 (Subsidie/contract van de Amerikaanse NIH)
- U01CA062505 (Subsidie/contract van de Amerikaanse NIH)
- U01CA062490 (Subsidie/contract van de Amerikaanse NIH)
- U01CA069856 (Subsidie/contract van de Amerikaanse NIH)
- UM1CA186690 (Subsidie/contract van de Amerikaanse NIH)
- UM1CA186717 (Subsidie/contract van de Amerikaanse NIH)
- UM1CA186709 (Subsidie/contract van de Amerikaanse NIH)
- N01CM00100 (Subsidie/contract van de Amerikaanse NIH)
- P30CA047904 (Subsidie/contract van de Amerikaanse NIH)
- NCI-2011-02500 (Register-ID: CTRP (Clinical Trial Reporting Program))
- CDR0000700997
- UPCI 10-115
- UPCI-10-115
- 8808 (Andere identificatie: CTEP)
- 8808 (Andere identificatie: UPMC Hillman Cancer Center)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .